ICARES Medicus (6612) reported revenue of NT$105.5 million for Oct 2026, +15.2% year on year and -4.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.11 billion (+20.8% year on year).
Year-on-year revenue growth: 9 months in a row. →
In Oct 2026, it ranked No. 70 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$105.5 million | +15.2% | -4.9% |
| Sep 2026 | NT$110.9 million | +36.0% | -22.3% |
| Aug 2026 | NT$142.8 million | +45.7% | +32.0% |
| Jul 2026 | NT$108.2 million | +28.8% | -6.8% |
| Jun 2026 | NT$116.1 million | +30.2% | -1.8% |
| May 2026 | NT$118.2 million | +43.3% | +4.2% |
| Apr 2026 | NT$113.4 million | +16.2% | +3.0% |
| Mar 2026 | NT$110.1 million | +7.3% | -2.6% |
| Feb 2026 | NT$113.1 million | +7.1% | +50.0% |
| Jan 2026 | NT$75.4 million | -15.7% | -33.2% |
| Dec 2025 | NT$112.8 million | +51.6% | +18.6% |
| Nov 2025 | NT$95.1 million | -2.5% | +3.8% |
| Oct 2025 | NT$91.6 million | +7.8% | +12.3% |
| Sep 2025 | NT$81.6 million | +1.8% | -16.8% |
| Aug 2025 | NT$98 million | +0.2% | +16.7% |
| Jul 2025 | NT$84 million | +6.3% | -5.8% |
| Jun 2025 | NT$89.1 million | +28.9% | +8.1% |
| May 2025 | NT$82.5 million | +43.4% | -15.5% |
| Apr 2025 | NT$97.6 million | +67.5% | -5.0% |
| Mar 2025 | NT$102.7 million | +50.4% | -2.7% |
| Feb 2025 | NT$105.5 million | +119.7% | +18.0% |
| Jan 2025 | NT$89.4 million | +100.1% | +20.2% |
| Dec 2024 | NT$74.4 million | +105.9% | -23.8% |
| Nov 2024 | NT$97.6 million | +118.7% | +14.9% |
| Oct 2024 | NT$84.9 million | +44.5% | +6.0% |
Jan–Oct 2026 cumulative: NT$1.11 billion (+20.8% YoY)
Other Biotech & Medical companies
Compare with peers: ICARES Medicus vs PEC / ICARES Medicus vs Lotus Pharm / ICARES Medicus vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16